EGFR and cancer: To determine whether thisstrategy can be generalized and to identifypotential prototype therapeutics, we developed a second molecularbident for mutant EGFR, a well-established driver of cancer signaling.Guided by structural analysis, we designed ZNL-0056, an ATP-competitiveinhibitor that targets both the Cys797 and Cys775 in the ATP bindingsite of EGFR.